HeartSciences (HSCS) EBITDA Margin (2021 - 2025)

HeartSciences' (HSCS) quarterly EBITDA Margin came in at 85713.23% in Q4 2025, up 13.1% on a QoQ basis from 98637.84% in Q3 2025.

HeartSciences (HSCS) EBITDA Margin (2021 - 2025) Analysis & Trends

HeartSciences (HSCS) has 5 years of EBITDA Margin data on file, last reported at 85713.23% in Q4 2025.

Quarterly EBITDA Margin changed N/A year-over-year to 85713.23% in Q4 2025, while the trailing twelve-month figure through Apr 2026 was 96946.89% (down 5310137.0% YoY) and the FY2026 annual result came in at 194787.38%, down 277425.0% from the prior year.
EBITDA Margin improved to 85713.23% in Q4 2025, from 98637.84% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 9011.84% in Q3 2021 to a low of 98637.84% in Q3 2025.
A 5-year average of 48780.2% and a median of 44418.82% in 2025 frame the typical range for EBITDA Margin.
Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 3567869 bps — and 2024, when it surged 5676700 bps.
Tracing HSCS's EBITDA Margin over 5 years: stood at 9011.84% in 2021, then sank by 396 bps to 44690.53% in 2022, then increased by 10 bps to 40254.95% in 2023, then soared by 74 bps to 10376.75% in 2024, then slumped by 726 bps to 85713.23% in 2025.
The last three EBITDA Margin figures came in at 85713.23% (Q4 2025), 98637.84% (Q3 2025), and 44147.1% (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Abbott Laboratories	199.12 Bn	193.52 Bn	7.27 Bn	13.44%
2	Stryker	128.79 Bn	125.32 Bn	4.50 Bn	25.18%
3	Medtronic	119.30 Bn	110.08 Bn	6.41 Bn	19.10%
4	Boston Scientific	73.50 Bn	72.96 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	52.11 Bn	47.86 Bn	1.35 Bn	29.48%
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	34.05 Bn	31.94 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn	10.30%
9	Steris	23.15 Bn	22.67 Bn	684.20 Mn	19.15%
10	HeartSciences	6.38 Mn	4.68 Mn	-	-

Download Data